TELA Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TELA Bio, Inc. (Nasdaq: TELA) on August 4, 2026, regarding events occurring on August 3, 2026. The filing addresses significant changes in executive leadership and the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and compensation arrangements.
Material Changes
- Departure of CEO and Director: Antony Koblish ceased serving as Chief Executive Officer and resigned from the Board of Directors effective August 3, 2026. The departure is treated as a termination without cause and did not result from any disagreement with the Company.
- Appointment of CEO and Director: Heather Getz was appointed Chief Executive Officer and a Class II Director effective August 3, 2026.
- Compensation and Equity:
- Base Salary: $650,000 annually.
- Target Bonus: 100% of base salary (prorated for the 2026 partial year).
- Initial Equity Grants:
- 1,365,000 Standard Stock Options.
- 1,005,000 Premium-Priced Stock Options (exercise price: greater of $0.90 or 15% premium to fair market value).
- 500,000 Restricted Stock Units (RSUs).
- Top-Up Provision: If the Company completes an equity financing within 18 months, Ms. Getz is entitled to additional grants to bring her total equity holdings to 5% of the post-financing share count.
- Severance Terms:
- Standard Termination: 12 months of base salary, pro-rated bonus, and health insurance continuation.
- Change of Control Termination: 18 months of base salary, 150% of target bonus, and acceleration of 100% of service-vesting conditions on equity awards.
Guidance, Outlook, and Risks
The filing contains no financial guidance or outlook. Management commentary highlights Ms. Getz's 25+ years of experience in healthcare and medical devices, including leading the turnaround of BioTelemetry, Inc. and securing over $1 billion in financing during her career. The primary risk noted is the uncertainty regarding the final terms of Mr. Koblish's separation agreement, which are expected to be disclosed in a subsequent amendment.
Investor Verification Checklist
- Verify the final terms of Antony Koblish's separation agreement once filed as an amendment to this 8-K.
- Confirm the exact exercise price of the stock options granted to Heather Getz based on the closing stock price on August 3, 2026.
- Monitor the Company's capital raising activities over the next 18 months to assess the potential dilution impact of the "Top-Up Grants" provision.
- Review the full text of the Getz Employment Agreement when filed as an exhibit to the Form 10-Q for the quarter ended September 30, 2026.